Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease

NCT03464136 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.

NCT NCT03464136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03464136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease
Lead sponsor
Janssen Scientific Affairs, LLC
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2018
Completion date
May 21, 2021
Enrollment
386 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease